KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates positive sentiment with strong product development and business updates, including EKTERLY's successful launch and positive feedback on side effects. The Q&A section highlights minimal adverse events and growing patient adoption, which are positive indicators. Despite some unclear management responses, the overall sentiment leans positive due to optimistic guidance and market growth projections.
Key Financial Performance
Net Revenue $1.4 million for the launch period, primarily from stocking orders by the specialty pharmacies and our commercial distribution network.
Total Operating Expenses $60.4 million, consisting of approximately $15 million in R&D expenses and approximately $45 million in SG&A expenses. The quarter-over-quarter increase in SG&A was driven primarily by external spending related to the EKTERLY launch.
Cash and Investments $191 million as of July 31, 2025. This balance, together with forecasted EKTERLY revenue, is expected to fund the company's operations into 2027.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA approval of EKTERLY: EKTERLY was approved as the first and only oral on-demand therapy for acute HAE attacks in adults and pediatric patients aged 12 and older. The U.S. launch began immediately after approval, with strong early uptake and positive community response.
Global expansion of EKTERLY: Regulatory progress includes a positive CHMP opinion in Europe, marketing authorization in the U.K., and anticipated approval in Japan and Canada. A staged launch in Europe is planned over the next 12-18 months, with a U.K. launch expected in early 2026.
U.S. market penetration: Almost 5% of the U.S. HAE population has submitted a prescription for EKTERLY. Early demand is coming from patients previously on other therapies, with 460 patient start forms received within 8 weeks of launch.
Physician engagement: 253 unique prescribers have been activated, with 38% starting multiple patients on EKTERLY. The sales team has reached 72% of the physician base, including 96% of Tier 1 physicians.
Financial performance: First sales of EKTERLY generated $1.4 million in net revenue during the launch period. Operating expenses for the quarter were $60.4 million, with $191 million in cash and investments available to fund operations into 2027.
Commercial infrastructure: Investments in commercial infrastructure prior to approval have facilitated a successful launch, with KalVista Care hub services operational to support patient access and financial needs.
Strategic focus on EKTERLY: The company is prioritizing EKTERLY as a foundational therapy for HAE, aiming to redefine the standard of care and drive global expansion.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Reimbursement Challenges: The process of securing patient access and reimbursement in the U.K. and other regions involves health technology assessments and negotiations, which could delay broad availability and impact revenue timelines.
Market Access and Competition: Formal coverage policies in the U.S. typically take up to 6 months to establish, potentially limiting initial patient access. Additionally, competition from existing injectable therapies and other on-demand treatments could impact market penetration.
Financial Sustainability: The company reported $60.4 million in operating expenses for the quarter, driven by the EKTERLY launch, and anticipates similar expenses moving forward. This could strain financial resources despite having $191 million in cash and investments.
Global Expansion Risks: The staged launch in Europe and pending regulatory approvals in Japan and Canada introduce uncertainties in timelines and market entry, which could affect global revenue growth.
Operational Execution: The success of the EKTERLY launch depends on the effectiveness of the commercial team and infrastructure. Any missteps in execution could hinder adoption and revenue generation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Global Expansion of EKTERLY: KalVista anticipates a staged launch in Europe over the next 12 to 18 months, starting with Germany, pending approval. A U.K. commercial launch is expected in the first half of 2026, following NICE health technology assessment. Approval in Japan is anticipated by the end of 2025, with a launch through Kaken Pharmaceutical in early 2026. Discussions for regulatory filing in Canada and partnerships in other regions are ongoing.
Revenue and Financial Outlook: KalVista expects operating expenses to remain consistent for the remainder of 2025 as investments in the EKTERLY launch continue. The company forecasts that its cash and investments, along with EKTERLY revenue, will fund operations into 2027.
Market Penetration and Adoption: KalVista is targeting the top 1,000 HAE-treating physicians in the U.S., who account for 90% of prescriptions. Early adoption has been strong, with 253 unique prescribers activated and 38% prescribing EKTERLY to multiple patients. The company expects launch KPIs to evolve over future quarters.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you speak about the Quickstart program and the process for prior authorizations and medical exemptions?
A:The Quickstart program provides immediate access to EKTERLY at no charge. When a start form is submitted, KalVista works with the physician's office to pursue a medical exception to gain paid access. Once the medical exception is approved, the patient's next shipment is sent without delay and paid by the commercial or government payer. If the exception requires more time, KalVista will send a second shipment.
Q:What are the prescribing patterns for EKTERLY, and can patients use it chronically as needed?
A:Prescribing patterns vary, with some physicians requiring a visit and others using telehealth. Patients can use EKTERLY as needed, with prescriptions typically written as PRN (as needed) to allow flexibility based on the patient's burden of disease.
Q:What are the expectations for the 4,000 patients and caregivers signed up for EKTERLY updates?
A:The patient database has grown quickly, and there is a mix of individual patients and caregivers. Some clinicians may require in-office visits, while others may not. The frequency of visits depends on the physician's approach.
Q:What are the expectations for launch metrics and the possibility of sharing actual doses prescribed?
A:As the launch progresses into months 4, 5, and 6, KalVista plans to share more KPIs, including repeat prescribers, refills, and product utilization per patient. Currently, patients typically receive two boxes for their initial prescription, with refills depending on the physician's prescription.
Q:What percentage of the 460 start forms were for Quickstart, reimbursed, or from another source?
A:100% of the 460 start forms were for Quickstart. Paid shipments have started going out to patients where the medical exception process was completed quickly. The company has also seen its first refills on the paid side.
Q:What feedback has been received on side effects and retreatment rates?
A:Feedback on side effects has been minimal, with no reports of GI-related adverse events. Retreatment rates are in the low 20s, consistent with expectations and below the rate for Firazyr. Anecdotal feedback has been positive.
Q:What is the breakdown of the 460 start forms between July and August, and does this suggest a linear trajectory?
A:The growth in start forms has been linear, with no surges indicating a one-time event. The demand has been broad, including patients on prophylaxis and those with varying attack rates.
Q:What is the expected inventory level at specialty pharmacies?
A:Specialty pharmacies are expected to hold 2 to 4 weeks of inventory, consistent with other rare disease launches.
Q:What is the patient profile for EKTERLY adopters?
A:Early adopters include patients with a high burden of disease, but adoption has been seen across a wide range of patient types. The patient base aligns with the market share of current prophylaxis therapies.
Q:What is the expected timeline for transitioning open-label extension (OLE) patients to reimbursed scripts?
A:The OLE includes several dozen U.S.-based patients, and their transition to reimbursed scripts is part of the general demand uptake. There is no immediate large-scale transition.
Q:What has been the outcome of patient education and awareness efforts?
A:Efforts include local education programs and participation in events like the HAEA Patient Summit. These efforts have helped introduce EKTERLY to patients and their families, contributing to adoption.
Q:What is the progress on securing formulary coverage and expectations for parity access?
A:Progress is as expected, with medical exceptions enabling paid access. Parity access to branded therapies is anticipated, with some exceptions requiring a step-through generic icatibant. Most patients have prior experience with generic icatibant, facilitating access.
Q:What are the assumptions behind the increased projected market growth for EKTERLY?
A:The increase reflects updated expectations for branded pricing, which is higher than initially estimated, and market growth projections.
Q:What do payers require to approve EKTERLY if a step-through generic icatibant is needed?
A:Payers may require evidence of failure on generic icatibant, which can include injection site reactions, difficulty administering subcutaneous injections, or other challenges. Physicians report that describing such failures to payers is straightforward.
Q:Will KalVista share percentage lives covered as a KPI?
A:KalVista plans to provide updates on payer efforts and access progress but has not committed to specific KPIs like percentage lives covered.
Q:When did EKTERLY become available post-approval, and how is revenue recognized?
A:EKTERLY became available approximately 10 days after approval. Revenue is recognized when the product is received by specialty pharmacies, with a lag before reaching patients.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the percentage of lives covered as a KPI, stating that updates on payer efforts and access progress would be shared in the future. Additionally, there was no clear breakdown of the 460 start forms between July and August, and the response on the timeline for transitioning OLE patients to reimbursed scripts lacked specificity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief
EKTERLY demand
EKTERLY launch
EKTERLY people
Europe
FDA approval
Financial
HAE attack
HAE physician
HAE treatment
KPIs
KalVista Pharmaceuticals
Officer
Pharmaceuticals update
SGA
UK
access
address
approval EKTERLY
community
conference
demand therapy
discussion
end
month
need EKTERLY
patient
people HAE
period
prescription
progress
result
sale
statement
today
KALV Transcript
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
Neutral3-25
KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-24
KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call summary presents a mixed picture. While EKTERLY's early market adoption and strong focus on high-burden patients are positive, the lack of specific financial guidance and uncertainty around revenue projections and pricing in Germany introduce caution. The Q&A reveals concerns about demand fluctuations and management's reluctance to provide clear revenue guidance, which tempers overall optimism. The neutral sentiment reflects these balanced positive and negative factors, with no strong catalysts or deterrents to drive significant stock price movement in the short term.
KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript
Positive9-11
The earnings call summary indicates positive sentiment with strong product development and business updates, including EKTERLY's successful launch and positive feedback on side effects. The Q&A section highlights minimal adverse events and growing patient adoption, which are positive indicators. Despite some unclear management responses, the overall sentiment leans positive due to optimistic guidance and market growth projections.
KALV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
